Howe Jolanda sold $264K of MIRM
Howe Jolanda (SVP, GLOBAL CONTROLLER) sold 2,594 shares of Mirum Pharmaceuticals, Inc. (MIRM) at $101.95 ($0.26M total) on 2026-06-17 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure confirms an officer open-market sale of $264,458.30 worth of MIRM shares under a pre-arranged 10b5-1 plan; it does not indicate a new corporate event.
Market read
Primarily useful for monitoring insider activity trends; unlikely to drive a standalone trading catalyst.
What to watch
The article provides sale size and price but not broader insider net activity, other concurrent Form 4s, or any changes in company fundamentals—so signal strength is limited.
Background
This is an SEC Form 4 insider transaction by Mirum Pharmaceuticals’ SVP Global Controller, executed 2026-06-17 and filed 2026-06-18.
Ticker impact
Mirum Pharmaceuticals Form 4 shows SVP Global Controller Howe Jolanda sold 2,594 shares at $101.95 under a 10b5-1 plan.
Low near-term impact; any effect is likely absorbed unless follow-on insider selling accelerates.
The filing is a disclosed open-market sale by an officer, explicitly under a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No sector read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, repeated officer sales can coincide with internal risk management or diversification, so traders may watch for clustering of similar filings.
Key entities
- issuerMirum Pharmaceuticals, Inc.
Subject of the Form 4 insider transaction; officer sale disclosed under Rule 10b5-1.
- insiderHowe Jolanda
SVP, Global Controller; sold 2,594 shares at $101.95.
